The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review

Francis MN. Bone sarcoma incidence and survival: tumours diagnosed between 1985 and 2009. NCIN. 2012;R12-05:1–13.

Google Scholar 

Gurney JG, Swensen AR, Bulterys M, Ries LAG, Smith MA, Linet M, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. Bethesda, MD: NIHPub; 1999. p. 99–110.

Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.

Article  PubMed  Google Scholar 

Price CH. Primary bone-forming tumours and their relationship to skeletal growth. J Bone Joint Surg Br. 1958;40-B:574–93.

Article  CAS  PubMed  Google Scholar 

Wick MR, Siegal GP, Unni KK, McLeod RA, Greditzer HG. Sarcomas of bone complicating osteitis deformans (Paget’s disease): fifty years’ experience. Am J Surg Pathol. 1981;5:47–59.

Article  CAS  PubMed  Google Scholar 

Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970;52:411–23.

Article  CAS  PubMed  Google Scholar 

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.

Article  PubMed  Google Scholar 

Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18.

Article  PubMed  Google Scholar 

Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012;2012:1–10.

Article  Google Scholar 

Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748–55.

Article  CAS  PubMed  Google Scholar 

Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994;12:2614–20.

Article  CAS  PubMed  Google Scholar 

Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98:2447–56.

Article  PubMed  Google Scholar 

Salah S, Ahmad R, Sultan I, Yaser S, Shehadeh A. Osteosarcoma with metastasis at initial diagnosis: current outcomes and prognostic factors in the context of a comprehensive cancer center. Mol Clin Oncol. 2014;2:811–6.

Article  PubMed  PubMed Central  Google Scholar 

Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.

Article  CAS  PubMed  Google Scholar 

Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26:407–14.

Article  CAS  PubMed  Google Scholar 

Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 2014;6:2126–33.

Article  CAS  PubMed  Google Scholar 

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.

Article  CAS  PubMed  Google Scholar 

Struck RF, Davis RL Jr, Berardini MD, Loechler EL. DNA guanine-guanine crosslinking sequence specificity of isophosphoramide mustard, the alkylating metabolite of the clinical antitumor agent ifosfamide. Cancer Chemother Pharmacol. 2000;45:59–62.

Article  CAS  PubMed  Google Scholar 

Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969;11:1101–10.

Article  CAS  PubMed  Google Scholar 

Dai X, Yue Z, Eccleston ME, Swartling J, Slater NK, Kaminski CF. Fluorescence intensity and lifetime imaging of free and micellar- encapsulated doxorubicin in living cells. Nanomedicine. 2008;4:49–56.

Article  CAS  PubMed  Google Scholar 

Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–41.

Article  CAS  PubMed  Google Scholar 

Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells. 1996;14:5–9.

Article  CAS  PubMed  Google Scholar 

Joo MW, Kang YK, Yoo CY, Cha SH, Chung YG. Prognostic significance of chemotherapy-induced necrosis in osteosarcoma patients receiving pasteurized autografts. PLoS One. 2017;12:1–11.

Article  Google Scholar 

Abou Ali B, Salman M, Ghanem KM, Boulos F, Haidar R, Saghieh S, et al. Clinical prognostic factors and outcome in pediatric osteosarcoma: effect of delay in local control and degree of necrosis in a multidisciplinary setting in Lebanon. J Glob Oncol. 2019;5:1–8.

PubMed  Google Scholar 

Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer. 2005;41:2079–85.

Article  CAS  PubMed  Google Scholar 

Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance- related protein) in osteosarcoma. Relationship with poor prognosis. Cancer. 1997;79:2336–44.

Article  CAS  PubMed  Google Scholar 

Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42–50.

Article  PubMed  Google Scholar 

Kumta SM, Zhu QS, Lee KM, Griffith J, Chow LT, Leung PC. Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma. Int Orthop. 2001;25:279–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watson MB, Lind MJ, Cawkwell L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs. 2007;18:749–54.

Article  CAS  PubMed  Google Scholar 

McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:1–16.

Article  Google Scholar 

Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, et al. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res. 1991;51:521–7.

CAS  PubMed  Google Scholar 

Yan XD, Li M, Yuan Y, Mao N, Pan LY. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep. 2007;17:1163–9.

CAS  PubMed  Google Scholar 

Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Int J Cancer. 1996;66:29–36.

Article  CAS  PubMed  Google Scholar 

Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, et al. Mechanisms of gene amplification and evidence of coamplification in drug- resistant human osteosarcoma cell lines. Genes Chromosom Cancer. 2009;48:289–309.

Article  CAS  PubMed  Google Scholar 

Roncuzzi L, Pancotti F, Baldini N. Involvement of HIF-1alpha activation in the doxorubicin resistance of human osteosarcoma cells. Oncol Rep. 2014;32:389–94.

Article  CAS  PubMed  Google Scholar 

Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol. 2008;19:1500–8.

Article  CAS  PubMed  Google Scholar 

Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol. 2004;15:151–60.

Article  CAS  PubMed  Google Scholar 

Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif